https://orcid.org/0009-0003-4798-1512
References
- Lääkekorvaukset kasvoivat vuonna 2022 – lääkkeiden uudet käyttötarkoitukset kasvattavat kustannuksia, mutta rinnakkaislääkkeiden käyttöönotto voisi tuoda säästöjä [Drug reimbursements increased in 2022 – new indications of drugs increase costs, but the introduction of synonymous preparations could bring savings] [website on the Internet]. Helsinki: Kela [Social Insurance Institution of Finland]; 2023. Finnish. Available from: https://www.kela.fi/yhteistyokumppanit-laakekorvaukset-ajankohtaista-apteekkitiedotteet/5198559/laakekorvaukset-kasvoivat-vuonna-2022-laakkeiden-uudet-kayttotarkoitukset-kasvattavat-kustannuksia-mutta-rinnakkaislaakkeiden-kayttoonotto-voisi-tuoda-saastoja. Accessed December 8, 2023.
- Aladul MI, Fitzpatrick RW, Chapman SR. Impact of infliximab and etanercept biosimilars on biological disease-modifying antirheumatic drugs utilisation and NHS budget in the UK. BioDrugs. 2017;31(6):533–544. doi:10.1007/s40259-017-0252-3
- Luukkanen SV, Tolonen HM, Airaksinen M, Saarukka LSM. The price and market share evolution of the original biologics and their biosimilars in Finland. BioDrugs. 2022;36(4):537–547. doi:10.1007/s40259-022-00540-y
- Kurki P, van Aerts L, Wolff-Holz E, Giezen T, Skibeli V, Weise M. Interchangeability of biosimilars: a European perspective. BioDrugs. 2017;31(2):83–91. doi:10.1007/s40259-017-0210-0
- Scheinberg M, Azevedo V. The future landscape of biosimilars in rheumatology: where we are where we are going. Autoimmun Rev. 2019;18(2):203–208. doi:10.1016/j.autrev.2018.09.005
- Statement on the scientific rationale supporting interchangeability of biosimilar medicines in the EU [website on the Internet]. Amsterdam: European Medicines Agency, Heads of Medicines Agencies; 2023. Available from: https://www.ema.europa.eu/en/documents/public-statement/statement-scientific-rationale-supporting-interchangeability-biosimilar-medicines-eu_en.pdf. Accessed December 8, 2023.
- Interchangeability of biosimilars – position of Finnish Medicines Agency Fimea [website on the Internet]. Helsinki: Finnish Medicines Agency Fimea; 2015. Available from: https://web.archive.org/web/20220331024125/https://fimea.fi/documents/542809/838272/29197_Biosimilaarien_vaihtokelpoisuus_EN.pdf. Accessed December 8, 2023.
- Switching between a reference product and a biosimilar [website on the Internet]. Oslo: The Norwegian Medicines Agency; 2017. Available from: https://www.legemiddelverket.no/en/news/switching-between-a-reference-product-and-a-biosimilar. Accessed December 8, 2023.
- Eduskunnan vastaus hallituksen esitykseen STM/2022/219 [Parliament’s response to the government’s motion STM/2022/219] [website on the Internet]. Helsinki: Valtioneuvosto [Finnish Government]; 2022. Finnish. Available from: https://valtioneuvosto.fi/paatokset/paatos?decisionId=0900908f80813f78. Accessed December 8, 2023.
- Tolonen H, Falck J, Kurki P, et al. Is there any research evidence beyond surveys and opinion polls on automatic substitution of biological medicines? A systematic review. BioDrugs. 2021;35(5):547–561. doi:10.1007/s40259-021-00493-8
- Tolonen H, Airaksinen M, Ruokoniemi P, Hämeen-Anttila K, Shermock K, Kurki P. Medication safety risks to be managed in national implementation of automatic substitution of biological medicines: a qualitative study. BMJ Open. 2019;9(10):e032892. doi:10.1136/bmjopen-2019-032892
- The ethical principles of research with human participants and ethical review in the human sciences in Finland - Finnish National Board on Research Integrity TENK guidelines 2019 [website on the Internet]. Helsinki: Finnish National Board On Research Integrity Tenk; 2019:3. Available from: https://tenk.fi/sites/default/files/2021-01/Ethical_review_in_human_sciences_2020.pdf. Accessed December 8, 2023.
- Klintrup K, Kastarinen H, Helminen S, Leinonen J, Saastamoinen L. Kela kehottaa: suosi biosimilaareja, kun määräät biologisia lääkkeitä [Social Insurance Institution of Finland urges: favor biosimilars when prescribing biological medicines]. Suom Laakaril. 2022;77(21–22):1012–1014. Finnish.
- Kela muistuttaa lääkäreitä edullisempien biologisten lääkkeiden määräämisestä [Social Insurance Institution of Finland reminds doctors to prescribe more affordable biological medicines] [website on the Internet]. Helsinki: Kela [Social Insurance Institution of Finland]; 2023. Finnish. Available from: https://tietotarjotin.fi/uutinen/694823/kela-muistuttaa-laakareita-edullisempien-biologisten-laakkeiden-maaraamisesta. Accessed December 8, 2023.
- Duggan B, Smith A, Barry M. Uptake of biosimilars for TNF-α inhibitors adalimumab and etanercept following the best-value biological medicine initiative in Ireland. Int J Clin Pharm. 2021;43(5):1251–1256. doi:10.1007/s11096-021-01243-0
- Kowalik K, Węgierska M, Barczyńska T, Jeka S. Pharmacoeconomic evaluation of costs of rheumatoid arthritis therapy with selected biological treatment. Reumatologia. 2018;56(6):340–345. doi:10.5114/reum.2018.80710
- Biotilsvarende legemidler kan byttes i apotek [Biosimilar medicines can be exchanged in pharmacies] [website on the Internet]. Oslo: Statens legemiddelverk [Norwegian Medicines Agency]; 2021. Norwegian. Available from: https://www.legemiddelverket.no/nyheter/biotilsvarende-legemidler-kan-byttes-i-apotek. Accessed December 8, 2023.